Pfizer (NYSE:PFE) Trading Up 1.2% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s stock price traded up 1.2% on Monday . The stock traded as high as $22.21 and last traded at $22.18. 16,697,014 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 40,143,759 shares. The stock had previously closed at $21.91.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group cut their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. Finally, Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Stock Up 1.5 %

The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $127.30 billion, a PE ratio of 15.92, a PEG ratio of 0.64 and a beta of 0.67. The business has a fifty day moving average of $25.09 and a 200 day moving average of $26.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Trading of Pfizer

Several hedge funds have recently added to or reduced their stakes in PFE. Passumpsic Savings Bank raised its stake in Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 1,998 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth about $1,499,000. Westside Investment Management Inc. boosted its holdings in Pfizer by 7.7% in the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 1,004 shares in the last quarter. Diamant Asset Management Inc. raised its holdings in Pfizer by 8.4% during the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 660 shares in the last quarter. Finally, Morse Asset Management Inc purchased a new stake in shares of Pfizer during the 3rd quarter worth approximately $2,649,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.